Sweden· SE-20230317000033
Feiba 100 E/ml Pulver och vätska till infusionsvätska, lösning
A medicinal product containing factor viii inhibitor bypassing fraction, registered in Sweden by Baxalta Innovations GmbH.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Factor Viii Inhibitor Bypassing Fraction
- Manufacturer
- Baxalta Innovations GmbH
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20230317000033
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Factor viii inhibitor bypassing fraction in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomFEIBA 100units/ml (1,000unit) powder and 10ml solvent for solution for infusion vialsTakeda UK Ltd
- FinlandFeibaBaxalta Innovations GmbH
- BelgiumFeiba 1000 UBaxalta Innovations
- CanadaFEIBA NFTAKEDA CANADA INC
- IrelandFEIBA 100 U/ml powder and solvent for solution for infusionBaxalta Innovations GmbH
- NorwayFeibaBaxalta Innovations GmbH
- GermanyFeibaTakeda Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Feiba
- Belgium · Feiba
- Bulgaria · Фейба
- Cyprus · Feiba
- Czechia · Feiba
- Germany · Feiba
- Denmark · Feiba
- Estonia · Feiba
- Spain · Feiba
- Finland · Feiba
- France · Feiba
- United Kingdom (Northern Ireland) · Feiba
- Greece · Feiba
- Croatia · Feiba
- Hungary · Feiba Nf
- Ireland · Feiba
- Italy · Feiba
- Lithuania · Feiba
- Latvia · Feiba
- Malta · Feiba
- Netherlands · Feiba
- Norway · Feiba
- Poland · Feiba Nf
- Portugal · Feiba Nf
- Romania · Feiba
- Slovenia · Feiba
- Slovakia · Feiba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3400986b-f56f-4989-a8b8-e93d83b07248 GET /v1/drugs/3400986b-f56f-4989-a8b8-e93d83b07248?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"SmPC",
"PL"
],
"se_npl_id": "20230317000033",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20230317000033",
"product_doc_link": "https://docetp.mpa.se/LMF/Feiba%20100%20E%20per%20ml%20powder%20and%20solvent%20for%20solution%20for%20infusion%20SmPC_09001bee83d4d788.pdf"
}See everything about factor viii inhibitor bypassing fraction.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.